<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43271">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02543034</url>
  </required_header>
  <id_info>
    <org_study_id>BTF14-KR-401</org_study_id>
    <nct_id>NCT02543034</nct_id>
  </id_info>
  <brief_title>Study of Petrolatum Gauze, Allevyn, and New Antiseptic Dressing, Betafoam® Dressing, in the Management of Split-Thickness Skin Graft Donor Site</brief_title>
  <official_title>Randomized, Controlled, Phase IV Study of Petrolatum Gauze, Allevyn, and New Antiseptic Dressing, Betafoam® Dressings, in the Management of Split-Thickness Skin Graft Donor Site</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mundipharma Korea Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mundipharma Korea Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, controlled, multi-centre, open-label, phase IV study.

      Total 81 patients will be enrolled in this study. Patients will be randomly assigned to
      Betafoam®, petrolatum gauze or Allevyn for donor site wounds after skin graft operation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy as measured by speed of wound healing</measure>
    <time_frame>6 months</time_frame>
    <description>Days needed for complete skin epithelialization in donor site wounds through routine swab culture (1 and 3 days) and visual assessment of wounds</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy as measured by adverse event collection</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Skin Graft</condition>
  <arm_group>
    <arm_group_label>Betafoam Wound Dressing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This contains 3% povidone iodine. Dressing will be routinely changed on day 3 and day 7, and can be replaced anytime due to various factors such as exudate control, dislodgement, or by investigators' clinical decision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Petrolatum Gauze</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dressing will be routinely changed on day 3 and day 7 and can be replaced anytime due to various factors such as exudate control, dislodgement, or by investigators' clinical decision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allevyn Wound Dressing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Allevyn adhesive wound dressing will be routinely changed on day 3 and day 7 and can be replaced anytime due to various factors such as exudate control, dislodgement, or by investigators' clinical decision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Betafoam Wound Dressing</intervention_name>
    <description>Foam dressing including Betadine iodine</description>
    <arm_group_label>Betafoam Wound Dressing</arm_group_label>
    <other_name>Betafoam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Petrolatum Gauze</intervention_name>
    <description>Gauze dressing</description>
    <arm_group_label>Petrolatum Gauze</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Allevyn Wound Dressing</intervention_name>
    <description>Foam dressing</description>
    <arm_group_label>Allevyn Wound Dressing</arm_group_label>
    <other_name>Allevyn</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who is same as or more than 19 years old

          2. Patients who will receive elective skin harvest operation

          3. Patients who is in lateral thigh or buttock with donor site area from 50 to 150 cm2

          4. Female patients who use method of contraception for the study

          5. Patients who voluntarily sign the informed consent

        Exclusion Criteria:

          1. Patients who are pregnant

          2. Patients who are known to have allergy to the dressing product including PVPI

          3. Known hyperthyroidism or other thyroid dysfunction such as nodular thyroid goiter,
             endemic goiter and Hashimoto's thyroiditis or patients who receive radioiodine
             therapy

          4. Co-morbidities which may adversely affect wound healing for example a patient with
             uncontrolled diabetes (HbA1c &gt; 8%), chronic renal failure, autoimmune disease, or
             immunocompromised patient

          5. Patients who receive anticoagulants, steroids or immunosuppressants

          6. Patients who have signs and symptoms of infection on enrollment and adversely affect
             wound healing

          7. Patients who have skin lesion such as Herpes zoster on donor site

          8. Burn of &gt;20% total body surface area

          9. If the donor site had been harvested on a previous occasion

         10. Patients who is limited cognitive ability

         11. Patients who are participating in or will plan to participate in other clinical
             trials

         12. Other various conditions that the investigators judge inappropriate for enrolment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jongwon Lee, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital, The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suyoun Yang, CR head</last_name>
    <phone>82-2-527-9219</phone>
    <email>suyoun.yang@mundipharma.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Buyeon Kim, CRM</last_name>
    <email>buyeon.kim@mundipharma.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jongwon Rhie</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 5, 2017</lastchanged_date>
  <firstreceived_date>August 31, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Infective Agents, Local</mesh_term>
    <mesh_term>Petrolatum</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
